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The objective of this study was to evaluate the effects of collagen peptide (CP) supplementation 
on the maintenance of knee joint condition in healthy university students belonging to a run­
ning club. Fifty-one male healthy university students were recruited from the running club of 
Josai University and were given a placebo or CP for 8 weeks. Subjective knee condition was 
evaluated by the Japanese Knee Osteoarthritis Measure (JKOM) score as the primary outcome. 
Secondary outcome was defined as changes in serum parameters. The total JKOM score and 
the JKOM II score for"pain and stiffness in the knees"were significantly lower in the CP group 
than in the placebo group at 4 weeks. Moreover, the JKOM ill score for"knee condition in daily 
life" in the CP group was lower than that in the placebo group at 4 and 8 weeks of intervention. 
At 4 weeks, interleukin-6 and 3-methylhistidine in serum were significantly elevated in the 
placebo group, whereas in the CP group, they were unchanged. No adverse events were 
observed. In summary, CP supplementation improved knee joint condition in male healthy sub­
jects belonging to a running club and also demonstrated the potential to suppress inflammation 
and reduce muscle tissue damage. 
(Jpn Pharmacol Ther 2019 ; 47 : 1455-62) 
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INTRODUCTION 
Collagen is a major structural component of connec-
tive tissues, accounting for about 30% of the total pro­
tein content in mammals. Gelatin, a heat-denatured 
product of collagen, has long been used as a compo-
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Table 1 Inclusion and exclusion criteria 
Inclusion 
·Subject must be�18 years of age 
·Male
·Subjects who perform a training with mechanical stress
Exclusion
·Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac disorder
·Subjects who have serious medical history
·Known food allergy to pork and gelatin
·Subjects with a history of gastrointestinal tract surgery
·Subjects who have chronic or acute infections
·Participating in other clinical trials at the start of this study
·Collagen peptide ingestion within 3 months prior to enrollment
·Continuous ingestion of supplements in affected joint pain within 3 months prior to start enrollment
·Subjects were judged inappropriate by a doctor
·Subjects with habit of smoking or excessive alcohol consumption
nent of food due to its gel-forming ability. Collagen 
peptide (CP) can be formed by hydrolyzing gelatin 
with an enzyme. CP is widely used as supplements.1'2 ) 
lwai, et al. reported that several food-derived CP were 
identified in human blood after the oral ingestion of 
CP.3) Moreover, Oesser, et al. determined the bioavail­
ability of CP after oral administration in mice using 
14C-labeled CP. The distribution of labeled amino 
acids in cartilage was confirmed, and they were still 
present 192 h after administration. This means that CP 
are almost completely absorbed and accumulated in 
some tissues such as articular cartilage. 4) On the basis 
of these results, several clinical studies were per­
formed to examine the joint-protective effects of CP. 
For example, Kumar, et al. demonstrated that the 
ingestion of 5 g of CP for 13 weeks significantly 
improved the Western Ontario and McMaster U niver­
sities Osteoarthritis Index (WOMAC) score used for 
the evaluation of joint pain and the visual analog scale 
(VAS) score, which is an indicator of pain in osteoar­
thritis (OA) patients. s) Moreover, McAlindon, et al. 
reported that proteoglycan concentrations in hyaline 
cartilage of patients with mild OA increased within 13 
weeks after the ingestion of 5 g of CP. 6) 
Several studies have examined the effect of CP in 
preventing the occurrence of injuries or knee pain in 
healthy individuals and university athletes. 7-9) It is 
particularly important for athletes to avoid injuries as 
well as to improve their competitive skills. Endurance 
athletes are at particular risk for overuse injuries or 
exercise-related joint pain.9) Furthermore, there are 
few large clinical trials to examine the effects of CP in 
maintaining knee joint condition in healthy subjects. 
In this context, more clinical trials are needed to 
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investigate the effects of CP with the aim of improv­
ing knee pain or maintaining knee joint condition in 
endurance athletes or healthy individuals. 
In the present study, we performed a randomized, 
double-blind, placebo-controlled clinical trial aimed 
at evaluating the effects of CP supplementation with 
respect to the maintenance of knee joint condition in 
male healthy university students belonging to a run­
ning club. 
MATERIALS AND METHODS 
1 lnvestigational products 
In this study, CP derived from porcine skin (average 
molecular weight 3500-7000; Nitta Gelatin Inc., 
Japan) were used and a placebo (maltodextrin) was 
purchased from Matsutani Chemical Industry Co., Ltd. 
(Itami, Japan). All preparations were of food grade. 
2 Study design 
This double-blind, placebo-controlled, randomized, 
clinical study was carried out at Josai University. It 
was approved by the Ethics Committee of Josai Uni­
versity (No. A27-7), registered with the University 
Hospital  Medical Information Network (No. 
000023033), and conducted in accordance with the 
Ethical Guidelines for Medical and Health Research 
Involving Human Subjects published by the Ministry 
of Health, Labour and Welfare of Japan and the Decla­
ration of Helsinki. A total of 51 male healthy univer­
sity students, 18 to 2 1  years of age, were recruited 
from the running club of Josai University and were 
screened for eligibility using the inclusion-exclusion 
criteria defined in Table 1. Only healthy students who 
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Number of Individuals 
(n=51) 
Randomized Subjects 
(n=51) 
Placebo Group 
(n=25) 
Dropped out 
(n=4) 
Completed study 
(n=21) 
CP Group 
(n=26) 
Dropped out 
(n=1) 
Completed study 
(n=25) 
Fig. 1 The method for selecting subjects 
for the intervention study 
Fifty-one subjects were randomly assigned 
to the CP or placebo group. A total of 25 sub­
jects in the CP group and 21 subjects in the 
placebo group completed the study. 
were diagnosed as having no OA by an attending phy­
sician participated in this study. Written informed con­
sent was obtained from the 51 subjects who fulfilled 
the entry criteria and did not meet the exclusion crite­
ria. Subjects were randomly assigned to the CP or pla— 
cebo group. The subjects were advised to consume CP 
or placebo orally at 5 g/day in their free time. A dou­
ble-blind method was adopted in which an assign­
ment table was created using random numbers so that 
age, BMI, and other factors at the time of participation 
were not imbalanced between the two groups. How­
ever, in case of an emergency in which a serious con­
dition occurred in the subjects, the minimum neces­
sary inforn誼tion was disclosed. The intervention test 
period was 8 weeks. At baseline, after 4 weeks, and at 
the end of the intervention period, Japanese Knee 
Osteoarthritis Measure (JKOM) score assessment and 
blood testing were carried out. 
3 Primary outcome 
Subjective knee condition was evaluated by JKOM 
score at baseline and at 4 and 8 weeks of follow-up: 
this was taken as the primary outcome. JKOM is a 
self-administered questionnaire based on a patient's 
subjective evaluation, consisting of 25 items in four 
Table 2 Demographic data of a double-blind, pla­
cebo-controlled, randomized trial in male 
healthy university students belonging to a 
running club 
Age (y) 
Height (cm) 
Weight (kg) 
BMI(kg/mり
Results are mean士 SD.
CP, collagen peptide 
Placebo 
(n=21) 
18.9 士1.1
169.2 土4.1
55.9 士5.4
19.8 士1.1
CP 
(n =25) 
19.5 土1.3
170.6 土4.6
57.6 土3.7
19.5 土1.3
subcategories: JKOM II (pain and stiffness in the 
knees; 0-32 points), JKOM ill (knee condition in 
daily life; 0-20 points), JKOM N (general activities; 
0-20 points), and JKOM V (health condition; 0-8
points). The total JKOM score was assessed by sum­
ming the scores from subcategories, with 100 points as
10) the maximum score. In each evaluation scale, a
higher value indicates a worse condition.
Knee pain was evaluated individually at baseline 
and at 4 and 8 weeks of follow-up, using a VAS. The 
VAS score represented the degree of knee pain, with a 
large value indicating severe knee pain. 
4 Secondary outcome 
Secondary endpoints were defined as changes in 
serum parameters. The serum parameters assessed 
were blood urea nitrogen (BUN), lactate dehydroge­
nase, creatine phosphokinase, aspartate aminotransfer­
ase, alanine aminotransferase, creatinine, tumor necro­
sis factor-a (TNF-a), C-reactive protein, interleukin-
6 (IL-6), and 3-methylhistidine (3-MH). 3-MH 
corrected with creatmme was used as a marker of 
muscle tissue damage. 
5 Statistical analysis 
Data are presented as mean士 standard deviation (SD). 
All statistical analyses were performed using SPSS 
version 25.0 for Mac. Mann-Whitney U-test was used 
to compare means between CP and placebo groups. 
Friedman's test was used to evaluate the change in 
score at each visit. P-values<0.05 were considered 
statistically significant. The analysis was supported by 
per-protocol methods. 
1457 
??????リポジトリJURA
Jpn Pharmacol Ther (薬理と治療） vol. 47 no. 9 2019 
Table 3 Difference in the JKOM and VAS scores according to CP consumption in male healthy 
university students belonging to a running club 
Group 
JKOM Total Score (0-100 points) Placebo 
CP 
JKOM II (Pain and stiffness in the knees, Placebo 
0-32 points) CP 
JKOMIII (Knee condition in daily life, Placebo 
0-20 points) CP 
JKOMN (General activities, 0-20 points) Placebo 
CP 
JKOMV (Health condition, 0-8 points) Placebo 
CP 
VAS (Degree of knee pain, mm) Placebo 
CP 
Results are mean土SD.
CP, collagen peptide 
* P<0.05 (Placebo vs. CP), #P<0.05 (vs. Baseline)
RESULTS 
1 Baseline characteristics 
A total of Fifty-one male healthy university students 
belonging to a running club met the inclusion criteria 
and were randomized to the placebo (n = 25) or CP 
groups (n = 26). Forty-six of the Fifty-one subjects 
completed the study correctly, representing the evalu­
ated per-protocol population. One subject in the CP 
group and four in the placebo group dropped out 
because of individual circumstances that were not 
related to any side e:ff ects caused by ingesting the CP 
or placebo (Fig. 1). Baseline demographic character­
istics of the study participants (n =46) are shown in 
Table 2. No statistically significant differences 
between the CP and placebo groups were detected. 
2 JKOM scores 
The JKOM scores of subjects in the CP and placebo 
groups at baseline and at 4 and 8 weeks are shown in 
Table 3. There was no significant difference in the 
JKOM scores at baseline between the CP and placebo 
groups. However, the total JKOM score significantly 
decreased at 8 weeks compared with the score at base­
line, in both CP and placebo groups. There were no 
significant changes in the scores in each of the four 
subcategories from those at baseline at 4 and 8 weeks 
in both CP and placebo groups. 
The total JKOM score at 4 weeks was signifi­
cantly lower in the CP group than in the placebo 
group. The JKOM II score for "pain and stiffness in 
the knees" and the JKOM ID score for "knee condition 
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n Baseline 4week 8 week 
21 4.43 土6.34 3.57士4.53 1.90 士 4.17#
25 3.00 土4.01 1.16 土1.21* 0.48土0.82#
21 1.43土3.31 1.33 土2.39 0.48土 2.18
25 1.04士2.68 0.16士0.47* 0.04士0.20
21 0.86士1.96 0.57 土1.12 0.67 士2.20
25 0.60 士1.78 0.04 土0.20* 0.00 土o.oo*
21 1.19 土1.97 0.76 土1.26 0.43土 0.87
25 0.64 士0.95 0.60 土0.96 0.24士0.60
21 0.95 土0.86 0.90 士1.09 0.38土0.59
25 0.72 土0.84 0.36士0.57 0.20 土0.41
21 19.5 土20.7 19.0 土22.7 12.2 土19.1
25 18.5士20.4 8.6 土15.7 18.4 士26.1
in daily life" at 4 weeks in the CP group were signifi­
cantly lower than those in the placebo group. Further­
more, the JKOM ID score for "knee condition in daily 
life" in the CP group was lower than that for the pla— 
cebo group at 8 weeks of intervention. There were no 
significant differences in the JKOM IV score for "gen­
eral activities" and the JKOM V score for "health 
condition" between the CP and placebo groups at all­
time points. 
3 VAS score 
The VAS scores of subjects in the CP and placebo 
groups at baseline, 4 weeks, and 8 weeks are shown in 
Table 3. There were no changes in the VAS scores at 4 
and 8 weeks compared with that at baseline in either 
group. Furthermore, there was no difference between 
the CP group and the placebo group at all-time points. 
4 Blood parameters 
The changes of serum parameters are shown in Table 
4. The serum concentration of IL-6, a cytokine that
plays a central role in inflammation, significantly
increased in the placebo group at 4 weeks from base­
line. Serum 3-MH, a marker of muscle protein degra— 
dation, ll) increased in the placebo group at 4 weeks
from baseline. There were no significant changes in
IL-6 and 3-MH levels in the CP group.
As part of the safety assessment, various bio­
chemical parameters in serum were also analyzed. 
BUN at 8 weeks from baseline was significantly 
increased in the CP group but not in the placebo 
group. BUN level at 4 weeks from baseline in the CP 
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Table 4 Difference in serum parameters according to CP consumption in male healthy university 
students belonging to a running club 
Group n Baseline 4week 8 week 
Inflammation markers 
TNF-a (pg/mL) Placebo 21 0.65 士0.15 0.66土0.13 0.73土0.29
CP 25 0.62土〇.16 0.64士 0.14 0.70 土0.18
IL-6 (pg/mL) Placebo 21 0.50土0.32 0.80土0.64# 0.82土1.00
CP 25 0.55土0.33 0.86土1.54 0.92土1.22
CRP (mg/dL) Placebo 21 0.03土0.02 0.04士 0.04 0.08土0.22
CP 25 0.05 士 0.13 0.10士 0.29 0.06士 0.08
Muscle damage marker 
3-MH (nMOL/mL) Placebo 21 3.92士0.65 4.34士 0.84# 4.24士 0.76
CP 25 4.28土〇.63 4.06土0.63 4.35土0.81
Safety markers 
BUN (mg/dL) Placebo 21 15.7土3.4 16.0土3.9 18.2土3.2
CP 25 17.4土3.8 18.0士 3.0* 20.0士 3.1#
LDH (U/L) Placebo 21 240土99 236土89 242土99
CP 25 246士 89 249士 75 268士 95
CPK (U/L) Placebo 21 480 土358 463土353 368土171
CP 25 482士 319 552土448 569士 530
Creatinine (mg/ dL) Placebo 21 0.75土0.08 0.76土0.08 0.79土0.10#
CP 25 0.78土0.06 0.77土0.06 0.80土0.06
AST (U/L) Placebo 21 37土18 35士 16 32士 8
CP 25 39土20 41士 19 45土43
ALT (U/L) Placebo 21 30土13 28土10 28土7
CP 25 27土15 27士 13 29土15
Results are mean土SD.
CP, collagen peptide; TNF-a, tumor necrosis factor-a ; IL-6, interleukin-6; CRP, C-reactive protein; 3-
MH, 3-methylhistidine; BUN, blood urea nitrogen; LOH, lactate dehydrogenase; CPK, creatine phospho-
kinase; AST, aspartate aminotransferase; ALT, alanine aminotransferase 
* P<0.05 (Placebo vs. CP), #P<0.05 (vs. Baseline)
group was significantly higher than that in the placebo 
group. Creatinine at 8 weeks from baseline was sig­
nificantly increased in the placebo group but not in the 
CP group. These changes observed were not clinically 
significant, and the all data in both groups were 
showed no significant difference from the normal 
range. These data demonstrated the safety of CP sup­
plementation. None of the adverse events was consid­
ered to be associated with CP or placebo supplemen­
tation. 
DISCUSSION 
This study was established with the aim of clarifying 
the effects of CP supplementation with respect to 
maintaining knee joint condition in healthy subjects. 
We conducted a randomized, double-blind, placebo­
controlled clinical trial on male students belonging to 
a running club at Josai University. Subjective knee 
condition was evaluated by JKOM score as the pri-
mary outcome of this study. JKOM is a measure of 
subjective symptoms involving an improvement on 
WOMAC, a QOL evaluation system for OA patients, 
adapted to the lives of Japanese people; it is widely 
used for Japanese knee joint research.10) JKOM con­
sists of 25 items that cover four subcategories: JKOM 
II for pain and stiffness in the knees, JKOM ill for 
knee condition in daily life, JKOM IV for general 
activities, and JKOM V for health condition. Patients 
with knee OA and individuals with pain or discomfort 
in the knees show higher total JKOM score or subcat­
egory scores. 
The results obtained here showed that the total 
JKOM score at 4 weeks was significantly lower in the 
CP group than in the placebo group (Table 3). Fur­
thermore, the JKOM II score for"pain and stiffness in 
the knees" and JKOM ill score for "knee condition in 
daily life" at 4 weeks in the CP group were also sig­
nificantly lower than those in the placebo group. Our 
results showed that continuous CP ingestion can 
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improve knee joint discomfort resulting from running 
long distances and not caused by OA. 
It has been reported that oral administrated CP is 
transferred to the blood in the form of di-peptides, 
such as Pro-Hyp, these peptides remain in a blood for 
a long time. 12) Due to its physiological role in the 
organism, Pro-Hyp is considered to be a bioactive 
compound. Study with labelled Pro-Hyp have shown 
that an amount of Pro-Hyp could be detected in skin 
and cartilage after orally administered [ 14C] Pro­
Hyp. 13) Importantly, orally administered Pro-Hyp 
inhibited phosphorus-induced loss of chondrocytes 
and thinning of the articular cartilage in mice. Further­
more, results from an in vitro study demonstrated that 
Pro-Hyp suppressed the hypertrophic differentiation 
of chondrocyte, which is involved in involved in the 
pathogenesis of OA and induced glycosaminoglycan 
synthesis by chondrocyte.14) Pro-Hyp also stimulated 
cultured synovial cells to synthesize hyaluronic acid, 
which is present in the synovial fluid in synovial 
joints.15) In addition, CP has reported to have a chon­
droprotective effect on OA by inhibiting the degenera­
tion of type II collagen which is found primarily in 
the cartilage and the expression of matrix metallopro­
teinase (MMP)-13 (an important type II collagen­
degrading enzyme) .16) It can be speculated that Orally 
administered CP suppresses the degradation of type II 
collagen, and CF-derived Pro-Hyp enhances the pro­
duction of hyaluronic acid and glycosaminoglycans by 
synovial cells and chondrocytes thereby exhibiting 
chondroprotective action in healthy male subjects. 
The differences in total JKOM score and JKOM 
II score between the CP and placebo groups were sig­
nificant at 4 weeks, but at 8 weeks, they became insig­
nificant. This apparent loss of the effect of CP inges­
tion at the end of the study might be ascribed to the 
reported pain score being low at the beginning of this 
study. In this experiment, the mean VAS score (土SD)
at baseline was 18.5 (土20.4)in the CP group and 19.5
（土20.7) in the placebo group. On the basis of previ­
ous studies, patients with VAS scores of 30 mm or less 
were defined as having mild pain. 17.1s) It can be specu­
lated that, for this study's subjects, the effect of CP 
was not obvious in the later period, possibly because 
the subjects were less symptomatic at that phase. 
However, the differences in the JKOM ill score for 
activities of daily living between the CP and placebo 
groups were maintained at the end of the study. It is 
indicated that continuous CP ingestion leads to 
improvement in the activities of daily life in healthy 
subjects. 
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Another analysis was conducted to investigate 
whether CP ingestion affected the serum parameters of 
the subjects. It has been reported that inflammatory 
cytokines such as TNF-a and IL-6 are elevated in 
patients with OA. 1 9) In this study, the level of the 
inflammatory cytokine IL-6 at 4 weeks was signifi­
candy increased compared with that at baseline in the 
placebo group (Table 4). IL-6 level in the CP group 
did not change through the intervention, but the differ­
ence between the groups was not significant at any 
time point. Although the involved mechanism is not 
fully understood, CP are considered to have anti­
inflammatory effects, as reported in several studies. 
CP administration to post-traumatic OA model mice 
showed a chondroprotective effect and further showed 
an anti-inflammatory response to decrease the expres­
sion of TNF, an inflammatory cytokine, in the syno­
vial membrane.20) Furthermore, the collagen-derived 
peptides Pro-Hyp and Hyp-Gly inhibited TNF-a­
induced Inflammatory response in endothelial cells. 21) 
Based on these studies, it can be assumed that Pro­
Hyp and Hyp-Gly derived from orally administered 
CP suppress the inflammatory response of endothelial 
cells, thereby exhibiting anti-inflammatory effects. 
It has been reported that, in patients with knee 
OA, in addition to the degeneration of articular carti­
lage and reduction of cartilage components such as 
proteoglycan, the muscle mass, and muscle strength 
near the knees, such as at the quadriceps muscle, are 
reduced. 22) Against this background, in this study, we 
demonstrated that serum 3-MH, a marker of muscle 
tissue damage, at 4 weeks was significantly increased 
from the level at baseline in the placebo group, but CP 
supplementation suppressed this elevation (Table 4). 
Recently, the effects of CP on muscle tissues have 
been reported. For example, a combination of CP sup­
plementation and resistance training improved body 
composition by increasing lean body mass and muscle 
strength. 23) Kitakaze, et al. also reported that the col­
lagen-derived dipeptide (Hyp-Gly) can induce myo­
genie differentiation and myotube hypertrophy by 
activating the PI3K/ Akt/mTOR pathway. 24) More­
over, Shimizu, et al. suggested that the oral adminis­
tration of Pro-Hyp and Hyp-Gly resulted in the 
upregulation of gene expression related to muscle 
function in DNA microarray analysis in skin barrier 
dysfunction model mice. 25) Praet, et al. recently 
reported that oral supplementation of specific CP may 
accelerate the clinical benefits of a well-structured 
calf-strengthening and return-to-running program in 
Achilles tendinopathy patients. 26) Therefore, it may be 
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possible that CP supplementation can lead to  
decreased knee discomfort due to the muscle-mainte­
nance or tendon-protective properties provided by 
specific peptides such as Pro-Hyp and Hyp-Gly. 
There were some limitations in this study. First, 
JKOM is a self-managed questionnaire based on 
patients'subjective assessment. Although JKOM has 
been validated, a more objective assessment of knee 
condition by physicians may be needed. Second, our 
results cannot be extrapolated to all young Japanese 
men because of the limited number of participants 
studied here, who belonged to the running club of a 
particular university. 
CONCLUSIONS 
In conclusion, our data suggest that the continuous 
ingestion of CP improved knee discomfort in male 
healthy subjects belonging to a running club. CP sup­
plementation was also demonstrated to have the 
potential to suppress inflammation and reduce muscle 
tissue damage. Because knee joint health is important 
to not only endurance athletes but also athletes spe­
cializing in other activities or elderly people, further 
study will be needed to explore the effects of CP sup­
plementation on knee joint health. Overall, these find­
ings suggest that CP are dietary supplements that can 
contribute to the improvement of knee joint condition 
that has been adversely affected by physical activities. 
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